Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Fatma M. Aboulnasr"'
Autor:
Nathan Shores, Partha K. Chandra, Lili Bao, Tong Wu, Kyoung-Sub Song, Darren P. Baker, Curt H. Hagedorn, Srikanta Dash, Fatma M. Aboulnasr, William C. Wimley, Shuanghu Liu, Luis A. Balart, Serge Y. Fuchs
Publikováno v:
The American Journal of Pathology. 184(1):214-229
A stable and persistent Hepatitis C virus (HCV) replication cell culture model was developed to examine clearance of viral replication during long-term treatment using interferon-α (IFN-α), IFN-λ, and ribavirin (RBV). Persistently HCV-infected cel
Autor:
Srikanta Dash, Asha Dash, Srinivas Chava, Luis A. Balart, Partha K. Chandra, Robert F. Garry, Sidhartha Hazari, Fatma M. Aboulnasr, Rajesh Panigrahi, Pauline Ferraris, Satyam Nayak, Tong Wu, Kyongsub Song, Ramazan Kurt
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 12, p e0141655 (2015)
PLoS ONE, Vol 10, Iss 12, p e0141655 (2015)
Background HCV replication in persistently infected cell culture remains resistant to IFN-α/RBV combination treatment, whereas IFN-λ1 induces viral clearance. The antiviral mechanisms by which IFN-λ1 induces sustained HCV clearance have not been d
Autor:
Rajesh Panigrahi, Pauline Ferraris, Luis A. Balart, Partha K. Chandra, Tong Wu, Srikanta Dash, Ramazan Kurt, Fatma M. Aboulnasr, Krzysztof Reiss, Yucel Aydin
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 5, p e0125962 (2015)
PLoS ONE, Vol 10, Iss 5, p e0125962 (2015)
Background Hepatic steatosis is a risk factor for both liver disease progression and an impaired response to interferon alpha (IFN-α)-based combination therapy in chronic hepatitis C virus (HCV) infection. Previously, we reported that free fatty aci
Autor:
Fatma M. Aboulnasr, Sidhartha Hazari, Partha K. Chandra, Feyza Gunduz, Luis A. Balart, Srikanta Dash, Darren P. Baker, Bret Poat
Publikováno v:
Virology Journal
Virology Journal, Vol 9, Iss 1, p 143 (2012)
Virology Journal, Vol 9, Iss 1, p 143 (2012)
Background Hepatic steatosis is recognized as a major risk factor for liver disease progression and impaired response to interferon based therapy in chronic hepatitis C (CHC) patients. The mechanism of response to interferon-alpha (IFN-α) therapy un